Preclinical study using circular RNA 17 and micro RNA 181c-5p to suppress the enzalutamide-resistant prostate cancer progression

Androgen-deprivation therapy (ADT) with newly developed antiandrogen enzalutamide (Enz) may increase the castration-resistant prostate cancer (CRPC) patients survival an extra 4.8 months. Yet eventually most patients may fail with development of Enz resistance. While recent clinical studies indicate...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Gang, Sun, Yin, Xiang, Zhendong, Wang, Keliang, Liu, Bo, Xiao, Guangqian, Niu, Yuanjie, Wu, Denglong, Chang, Chawnshang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425037/
https://www.ncbi.nlm.nih.gov/pubmed/30674872
http://dx.doi.org/10.1038/s41419-018-1048-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425037/
https://www.ncbi.nlm.nih.gov/pubmed/30674872
http://dx.doi.org/10.1038/s41419-018-1048-1

Ejemplares similares